1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S114-

  Rosell, R ^a   Gettinger, S N ^b   Bazhenova, L A ^c   Langer, C J ^d   Salgia, R ^e   Shaw, A T ^f   Narasimhan, N I ^g   Dorer, D J ^g   Kerstein, D ^g   Camidge, D R ^h  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g ARIAD PHARMACEUTICALS INC   (United States)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BRIGATINIB; CRIZOTINIB;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPOXIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX RATIO; SURVIVAL TIME; TREATMENT DURATION;

EID: 84991683188     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30245-3     Document Type: Article

References (0)